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Summary
Backgrounds: Systemic embolism is an important complication in patients with
rheumatic mitral stenosis (RMS). The mean platelet volume (MPV) is considered
a marker and determinant of platelet function since larger platelets are hemo-
statically more reactive than platelets of normal size, increasing the propensity
to thrombosis. The aim of this study was to investigate MPV in patients with RMS
and healthy control subjects.
Methods: We selected 30 consecutive patients with RMS and 31 consecutive healthy
age- and sex-matched control subjects. All subjects were in sinus rhythm. We mea-
sured MPV in a blood sample collected in EDTA.
Results: Demographic data of the RMS (mean age: 39.5± 9.9 years, 22 [71%] female)
and control groups (mean age: 39.2± 9.3 years, 20 [67%] female) were similar. The
MPV was signiﬁcantly higher in patients with RMS 8.8 (8.2—11.3) ﬂ than control
subjects 8.1 (7.1—9.3) (P < 0.001).
Conclusion: Elevated MPV might be considered as a marker of increased thromboem-
bolic risk in patients with RMS. We suggest that patients with high MPV values might
beneﬁt from antiplatelet therapy.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.∗ Corresponding author. Tel.: +90 3123569000;
fax: +90 3123569002.
E-mail address: byavuzmd@gmail.com (B. Yavuz).
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Table 1 Demographic features and laboratory parameters of patients with rheumatic mitral stenosis and control
subjects.
RMS (n = 30) Controls (n = 31) P-value
Age (years) 39.5± 9.9 39.2± 9.3 NS
Gender (M/F (%)) 8/22 (29/71%) 10/20 (33/67%) NS
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Mean values of the peak and mean gradients were
14.80± 5.85 and 7.09± 4.07, respectively.
The MPV was signiﬁcantly higher in patients with
RMS 8.8 (8.2—11.3) ﬂ than control subjects 8.1
Table 2 Echocardiographic parameters of patients
with rheumatic mitral stenosis and control subjects.
RMS (n = 30) Controls (n = 31) P-valuePLT (L ) 235± 68× 10
MPV (ﬂ) 8.8 (8.2—11.3)
urgical treatment can be performed [1]. Systemic
mbolism is an important complication in patients
ith RMS. A variety of abnormalities in parameters
f both coagulation and platelet aggregation were
reviously reported in patients with RMS [2].
The mean platelet volume (MPV), the accurate
easure of platelet size, is considered a marker
nd determinant of platelet function since larger
latelets are hemostatically more reactive than
latelets of normal size, increasing the propensity
o thrombosis [3]. Large platelets are known to
e hyperfunctional; they show greater aggregation
o ADP, collagen, or adrenaline and secrete more
hromboxane 2 per unit volume of cytoplasm [4].
levated MPV level has been shown to be an inde-
endent risk factor for cardiovascular disease [5].
The purpose of our study was to investigate MPV
n patients with RMS and a comparable group of
ealthy control subjects.
ethods
tudy population
e selected 30 consecutive patients with RMS
nd 31 consecutive healthy age- and sex-matched
ontrol subjects. Exclusion criteria were diabetes
ellitus, renal and hepatic failure (serum crea-
inine >1.5mg/dl, AST and ALT > 2 times upper
imit of normal), heart failure, hematological dis-
rders, acute or chronic infection, cancer, and
trial ﬁbrillation. All subjects were in sinus rhythm.
he protocol of this study was approved by the
ocal ethics committee, and informed consent was
btained from every subject participating in this
tudy.
iochemical measurementslood samples were drawn after a fasting period of
2 h. We measured MPV in a blood sample collected
n EDTA. The measurements were performed imme-
iately after blood sampling in order to prevent in
itro platelet activation. A Beckman Coulter Gen-233± 68× 10 NS
8.1 (7.1—9.3) <0.001
Hematology Analyzer was used for whole blood
ounts. The reference range for MPV in our hema-
ology laboratory is 6.9—10.8 ﬂ.
tatistical method
ata are demonstrated as mean± S.D. for normally
istributed continuous variables, median (mini-
um−maximum) for skew distributed continuous
ariables, and frequencies for categorical vari-
bles. Pearson Chi-square test was performed for
he comparison of categorical variables. Means
f normally distributed continuous variables were
ompared by ANOVA. Skew distributed continuous
ariables were compared by Mann—Whitney U-test.
tatistical Package for Social Sciences (SPSS) for
indows version 10.0 (SPSS Inc., Chicago, IL, USA)
as used for the analysis and P value of <0.05 was
onsidered as signiﬁcant.
esults
hirty patients with RMS and 31 control subjects
ere examined. Demographic data of the RMS
mean age: 39.5± 9.9 years, 22 [71%] female) and
ontrol groups (mean age: 39.2± 9.3 years, 20
67%] female) were similar. Baseline characteristics
f both groups are shown in Table 1.
The echocardiographic parameters of both
roups are presented in Table 2. Mean mitral
alve area was 1.65± 0.38 cm2 in the RMS group.EDD (cm) 4.7 ± 0.6 4.6 ± 0.6 NS
ESD (cm) 3.2 ± 0.7 3.1 ± 0.5 NS
EF (%) 60.3 ± 9.3 62.0 ± 5.6 NS
LA (cm) 4.6 ± 0.9 3.3 ± 0.4 <0.001
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RFigure 1 Distribution of MPV levels in patients with RMS
and normal controls.
(7.1—9.3) (P < 0.001). The distribution of MPV levels
in patients with RMS and normal controls is shown in
Fig. 1. There was no statistically signiﬁcant differ-
ence regarding platelet absolute count in patients
with RMS (235± 68× 109 L−1) and control subjects
(233± 68× 109 L−1). Mean platelet volume was not
signiﬁcantly correlated with age and echocardiog-
raphy parameters in patients with RMS.
Discussion
Systemic embolism is an important complication in
patients with RMS. Previous studies showed sev-
eral hemostatic abnormalities in patients with RMS
[6]. A hypercoagulable state has been reported in
patients with RMS who have both atrial ﬁbrillation
and sinus rhythm [7,8].
In addition to coagulation factors, platelets play
a vital role as systemic components of the hemo-
static system. They are critical to the activation of
intrinsic pathway factors. Patients with rheumatic
heart disease on oral anticoagulants may have
thromboembolic episodes, suggesting that platelets
may play an important role in the development of
such episodes. Kunishima et al. have demonstrated
that platelet activation occurs in peripheral blood
of patients with rheumatic mitral stenosis. They
also showed augmented platelet destruction [9].
Tengiz et al. found higher platelet aggregation in
patients with RMS than in controls [10]. Kataoka et
al. demonstrated that platelet activity signiﬁcantly
decreased after optimal percutaneous transluminal
mitral valvuloplasty [11].
Platelets are heterogeneous in size, density,
and reactivity. Larger platelets have a higher
thrombotic potential than normal-sized platelets.B. Yavuz et al.
emostatically reactive platelets, larger platelets,
ave more granules and adhesion receptors that
ave resulted in decreased bleeding time showing
ncreased activation [12].
It was shown that elevated MPV was related to
ncreased acute and long-term adverse cardiovas-
ular outcome [5]. Previous studies have shown
hat patients with acutemyocardial infarction (AMI)
nd other vascular conditions, such as renal artery
tenosis, pre-eclampsia, hyperlipidemia, and dia-
etes mellitus have larger platelets [4]. Yilmaz et
l. showed that MPV was increased in patients with
ilated cardiomyopathy and sinus rhythm having
eft ventricular thrombosis [13].
In our study we found that MPV was higher in
atients with RMS when compared to healthy con-
rol subjects. Peverill et al. evaluated spontaneous
cho contrast and various hematological param-
ters in a group of mitral stenosis patients who
ere undergoing investigation prior to percuta-
eous balloon mitral valvuloplasty [14]. They did
ot ﬁnd a signiﬁcant difference in MPV between
inus rhythm and atrial ﬁbrillation groups. In this
tudy, MPV was not studied in healthy control sub-
ects. Moreover, there was no correlation between
pontaneous echo contrast grade and platelet vari-
bles in the study group. Our data suggest that
ncreased MPV represents one possible mechanism
y which subjects with RMS may be at increased
hromboembolic risk.
onclusion
he biological and prognostic value of increased
PV is still controversial. Prospective, placebo-
ontrolled studies with large sample size using
ultivariable survival analysis are needed for prog-
ostic evaluation of increased MPV in patients
ith RMS. The elevated MPV might be considered
s a marker of increased thromboembolic risk in
atients with RMS. We suggest that patients with
igh MPV values might beneﬁt from antiplatelet
herapy.
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